Sky Zoster ranked first in sales of shingles vaccine last yr

Domestic market share 54%

Superiority over competitive products in convenience and price competitiveness

SK Bioscience announced on the 28th, citing IMS data, a global market research institute, that its self-developed shingles vaccine Sky Zoster achieved the top share in sales in the domestic market last year.

 

According to SK Bioscience, Sky Zoster's domestic market share last year reached 54% based on sales volume.

 

Quarterly by quarter, 51% in the first quarter, 52% in the second quarter, 56% in the third quarter, and 57% in the fourth quarter.

 

It is explained that it broke the record for the largest market share every quarter.

 

Sky Zoster is the world's second and Korea's first shingles vaccine developed by SK Bioscience based on its own technology.

 

SK Bioscience explained that Sky Zoster achieved 1 million doses in cumulative sales within two years after its launch in 2017 based on its excellent safety, immunogenicity, convenience, and reasonable price.

 

As a result of phase 3 clinical trial conducted on 824 adults aged 50 years or older at 8 domestic institutions including Korea University Guro Hospital, it was found that the antibody titer against the varicella-zoster virus increased by 2.75 times after vaccination compared to before Skyzoster vaccination.

 

Non-inferiority to the control vaccine was also demonstrated.

 

As a result of examining the incidence of adverse reactions that occurred 6 weeks after vaccination with Skyzoster, it was similar to that of the control vaccine group, and no serious adverse reactions showing a causal relationship with Sky Zoster were reported even during 26 weeks after vaccination.

 

According to the results of the post-marketing investigation of Sky Zoster announced by the Ministry of Food and Drug Safety in July of last year, as a result of analyzing 651 Sky Zoster inoculations for four years, no serious adverse drug reactions were reported after vaccination.

 

Sky Zoster is released in the form of a 'pre-filled syringe' containing one inoculation per injection, so it has the advantage of low contamination risk and convenient vaccination.

 

Unlike competitive products, the fact that the vaccine only needs to be vaccinated once is considered an advantage.

 

An official from SK Bioscience said, "There was a prediction that there would be a change in market share as a global pharmaceutical company's shingles vaccine entered Korea at the end of last year, but Skyzoster maintained its No.

 

1 position with its safety and reasonable price competitiveness.

 

Sky Zoster is also expanding its presence in overseas markets beyond Korea.

 

In May 2020, the first global approval was obtained in Thailand, followed by item approval from the Malaysian National Drug Administration (NPRA) in January.

 

In addition to these individual country permits, SK Bioscience plans to accelerate its efforts to target the global market by applying for WHO pre-qualification within this year.

 

Ahn Jae-yong, CEO of SK Bioscience, said, “As the world is rapidly aging, the importance of vaccination against shingles, which is vulnerable to the elderly, is growing.” I hope to play a role," he said.